A Phase 1b/2 Study of Idelalisib in Combination with BI 836826 in Subjects with Chronic Lymphocytic Leukemia
Sponsor: |
Gilead Sciences, Inc |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ4712 |
U.S. Govt. ID: |
NCT02538614 |
Contact: |
Nicole Lamanna: 646-317-5077 / nl2129@cumc.columbia.edu |
The purpose of the study is to see if a combination of idelalisib and BI 836826 can help control patients with Chronic Lymphocytic Leukemia (CLL) without serious side effects.
This study is closed
Investigator
Nicole Lamanna, MD
Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL)? |
Yes |
No |